Company Description
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems.
The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression.
It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder.
In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021.
The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Adi Zuloff-Shani |
Contact Details
Address: 1220 West 6th Avenue, Suite 101 Vancouver, BC V6H 1A5 Canada | |
| Phone | 973 536 1016 |
| Website | clearmindmedicine.com |
Stock Details
| Ticker Symbol | CMND |
| Exchange | NASDAQ |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 1892500 |
| CUSIP Number | 185053600 |
| ISIN Number | CA1850536006 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Adi Zuloff-Shani Ph.D. | Chief Executive Officer |
| Prof. Mark Haden M.S.W. | Vice President of Business Development |
| Mylene Touboul | Accounting Manager |
| Mary-Elizabeth Gifford | Chief of Global Impact |
| Adi Varon | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 20, 2026 | 6-K | Report of foreign issuer |
| Jul 17, 2026 | 6-K | Report of foreign issuer |
| Jul 16, 2026 | 6-K | Report of foreign issuer |
| Jul 13, 2026 | 6-K | Report of foreign issuer |
| Jul 10, 2026 | 6-K | Report of foreign issuer |
| Jul 7, 2026 | 6-K | Report of foreign issuer |
| Jun 29, 2026 | 6-K | Report of foreign issuer |
| Jun 22, 2026 | 6-K | Report of foreign issuer |
| Jun 18, 2026 | EFFECT | Notice of Effectiveness |
| Jun 18, 2026 | 6-K | Report of foreign issuer |